参芎心脉康汤治疗稳定型心绞痛的真实世界前瞻性观察研究
该研究为2019至2023年单中心前瞻性真实世界观察研究,纳入219例稳定型心绞痛患者,比较标准西医治疗(SBMT组101例)与参芎心脉康汤联合标准治疗(CTCM组118例),采用IPTW平衡基线。结果显示联合组在心绞痛症状评分、心电图、LVEF及LDL-C、CK、hs-CRP、cTnI等指标上显著改善,心血管事件无生存差异未达统计学显著。
要点
- 参芎心脉康汤联合标准治疗可改善稳定型心绞痛患者症状评分、心电图和LVEF。
- 联合组LDL-C、CK、hs-CRP、cTnI水平低于标准治疗组。
- 联合组心血管事件无生存获益未达统计学显著,安全性良好。
核心结论
- 在真实世界环境中,参芎心脉康汤联合标准西医治疗稳定型心绞痛安全,并与症状、功能和生化结局改善相关。
研究设计与样本
- 前瞻性、单中心、真实世界观察性研究,2019至2023年纳入219例稳定型心绞痛患者,注册号ChiCTR2100052872。
- 患者分标准西医治疗组(SBMT组,n=101)和参芎心脉康汤联合标准治疗组(CTCM组,n=118),采用逆概率治疗加权(IPTW)平衡基线协变量。
主要发现
- IPTW调整后基线特征均衡,CTCM组较SBMT组在心绞痛症状评分、心电图和左心室射血分数(LVEF)方面显著改善。
- CTCM组低密度脂蛋白胆固醇(LDL-C)、肌酸激酶(CK)、高敏C反应蛋白(hs-CRP)和心肌肌钙蛋白I(cTnI)水平更低。
- CTCM组心血管事件发生率降低,但心血管事件无生存期差异未达统计学显著。
临床怎么用
- 对稳定型心绞痛患者,可在标准西医治疗基础上联合参芎心脉康汤以改善症状、心电图和心功能指标。
- 联合治疗可能有助于降低LDL-C、CK、hs-CRP和cTnI等生化指标,但心血管事件硬终点获益尚不明确。
局限性
- 本研究为单中心真实世界观察性研究,样本量有限,结果需多中心随机对照试验进一步验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Shenxiong-Xinmaikang Decoction (SXXMKD), a modified traditional Chinese herbal formula, is widely used in clinical practice for stable angina pectoris (SAP). However, robust clinical evidence supporting its efficacy and safety is lacking. This study aimed to evaluate the real-world effectiveness and safety of SXXMKD as an adjunct to standard therapy for SAP. METHODS: This was a prospective, single-center, real-world observational study conducted between 2019 and 2023, enrolling 219 SAP patients (Registry: ChiCTR2100052872). Patients received either standard care alone (standard biomedical treatment group, SBMT group; n = 101) or SXXMKD combined with standard care (combined Traditional Chinese Medicine, CTCM group; n = 118). To minimize selection bias and balance baseline covariates, we applied inverse probability of treatment weighting (IPTW). Clinical outcomes were assessed at short- and long-term follow-up. RESULTS: After IPTW adjustment, baseline characteristics were well-balanced between the groups. Compared to the SBMT group, the CTCM group demonstrated significant improvements in angina symptom scores, electrocardiogram readings, and left ventricular ejection fraction (LVEF). Furthermore, the CTCM group showed lower levels of low-density lipoprotein cholesterol (LDL-C), creatine kinase (CK), high-sensitivity C-reactive protein (hs-CRP), and cardiac troponin I (cTnI). While the incidence of cardiovascular events was reduced in the CTCM group, the difference in cardiovascular event-free survival did not reach statistical significance. CONCLUSION: In a real-world setting, the addition of SXXMKD to standard biomedical treatment for SAP was safe and associated with improved symptomatic, functional, and biochemical outcomes. These findings suggest that SXXMKD is a promising adjunctive treatment for improving clinical outcomes in patients with stable angina. CLINICAL TRIAL REGISTRATION: https://www.chictr.org.cn/, identifier: ChiCTR2100052872.
引用
- Dong Y, Zeng K, Liang Y, et al. Efficacy and safety of Shenxiong-Xinmaikang Decoction in patients with stable angina pectoris: a real-world prospective observational study. Front Pharmacol. 2025. PMID: 40808695. doi:10.3389/fphar.2025.1591959
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。